louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06303323: Comparative Effectiveness of Qigong Exercise Versus Wu Dang Tai Chi Chuan in CVD Risk Individuals
Official title: Comparative Effectiveness of Qigong Exercise Versus Wu Dang Tai Chi Chuan on Exercise Capacity and Stress in CVD Risk Individuals
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cardiovascular Diseases
Risk Behavior, Health
Keywords: Qigong exercise
Wu Dang Tai Chi Chuan
Exercise capacity
CVD Risk individuals
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2024-03-12
Enrollment: 36
Sex: ALL
Minimum age (years): 30
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare whether the Qigong exercise or Wu Dang Tai Chi Chuan will be effective in improving exercise capacity and reducing stress in CVD-risk individuals. Based on preliminary data, Qigong and Tai-Chi may help treat anxiety and depression symptoms in patients with chronic illnesses as well as in healthy adults. Without the need for specialized equipment, Qigong and Tai-Chi are both readily adjustable mind-body exercises that may be done whenever and wherever. For this reason, Qigong and TaiChi should be extensively encouraged as ways to enhance emotional wellbeing

Detailed description: Since no comparison study has thus far been carried out in Pakistan which includes both interventions and very little literature is available. They belong to a group of Chinese exercises known for their efficacy in reducing blood pressure, stress, and quality of life and improving exercise capacity in patients with a high risk of CVD or CVD disease. These techniques are cost-effective treatment approaches and provide early outcomes. The positive results of this study would be helpful in the near future.

Eligibility criteria: Inclusion Criteria:

* According to the Framingham risk calculator 10% to 20%+ for moderate to high-risk
* Patients at risk of CVD (last 6 months)
* Patients with either HTN, dyslipidemia, or diabetes
* Patients with less than 45 scores on the Berg Balance scale
* Stress from moderate to severe on PSS
* No regular physical exercise for at least 1 year
* Willing to take part

Exclusion Criteria:

* History of stroke
* CVD
* Acute Infection
* Acute injury
* Any diagnosed psychological issue
* MSK disorders
* Member of marital arts/dance

Primary outcomes:
measure: Exercise Capacity
timeFrame: 6 weeks
measure: Stress
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Rawalpindi
country: Pakistan
facility: Pakistan Railway General Hospital
state: Punjab
Study officials:
affiliation: Riphah International University
name: Mehwish Waseem, MSPT-CPPT
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01401738: Results of Shoulder Arthroscopic Surgery for Rotator Cuff, Biceps Tendon, Labrum and Capsule
Official title: Results of Shoulder Arthroscopic Surgery for Rotator Cuff, Biceps Tendon, Labrum and Capsule
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Shoulder Arthroscopic Surgery
Keywords: Shoulder Arthroscopic Surgery
Lead sponsor: Taipei Medical University WanFang Hospital
Sponsor class: OTHER
First posted: 2011-07-25
Enrollment: 170
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Shoulder Arthroscopic Surgery patients

Brief summary: This study is a retrospective review of chart. Clinical results including range of motion, muscle power and scores will be recorded. Arthroscopic surgery of rotator cuff, labrum and capsule well be re-evaluated for clinical application.


Eligibility criteria: Inclusion Criteria:

* Shoulder lesions including capsule, biceps, rotator cuff which indicated for arthroscopic surgery

Exclusion Criteria:

* Open surgery for shoulder lesions
* Concomitant open and arthroscopic surgery

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Taipei Medical University - WanFang Hospital
Study officials:
affiliation: Taipei Medical University WanFang Hospital
name: Tai-Yuan Chuang
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01582438: An Open Label Access Study For Subjects Who Completed A1481156
Official title: A Local, Multicentre, Open Label Access Study, To Provide Sildenafil Therapy For Subjects Who Completed A1481156 Study And Are Judged By The Investigator To Derive Clinical Benefit From Continued Treatment With Sildenafil For Subjects In India
Study type: EXPANDED_ACCESS
Overall status: NO_LONGER_AVAILABLE
Conditions: Pulmonary Arterial Hypertension
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2012-04-20
Sex: ALL
Minimum age (years): 12
Maximum age (years): 30
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no

Brief summary: The purpose of this study is to provide sildenafil therapy to subjects who have completed the A1481156 study for the treatment of Pulmonary Arterial Hypertension (PAH) in India and are judged by the Investigator to derive clinical benefit from continued treatment with sildenafil citrate. Sildenafil citrate will be supplied for the treatment of Pulmonary Arterial Hypertension (PAH) until the subject continues to derive benefits from the treatment. The treating physicians (and the sponsor) will be responsible for reporting serious adverse events.


Eligibility criteria: Inclusion Criteria:

* Subjects who have completed study A1481156 and are judged by the Investigator to derive clinical benefit from continuous treatment with sildenafil citrate therapy.
* Subjects with pulmonary arterial hypertension (PAH ) being treated at a study site in India
* Subjects who are willing and able to comply with scheduled visits, treatment plan, and other study procedures

Exclusion Criteria:

* Pregnant or lactating female subjects.
* Current participation in other studies and during study participation, except for the A1481304 follow-up period.
* Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Hyderabad
country: India
facility: CARE Hospital
state: Andhra Pradesh
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT05258838: Tunisian National Registry on Psoriasis
Official title: Tunisian National Registry on Psoriasis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Psoriasis
Keywords: Psoriasis
Dermatology
Tunisia
Dacima
Lead sponsor: Dacima Consulting
Sponsor class: OTHER
Collaborators: name: Société Tunisienne de Dermatologie et de Vénéréologie
First posted: 2022-02-28
Enrollment: 1100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Hospitalized or outpatient subjects with psoriasis

Brief summary: National cross-sectional multicentric study to describe the epidemiological characteristics of patients with Psoriasis in Tunisia

Detailed description: PsoTReg is a Tunisian, descriptive, non-interventional, multicenter and cross-sectional clinical study performed in dermatology departments and outpatients clinics, of both public and private sectors. The study will enroll hospitalized and ambulatory patients with psoriasis disease, by successive inclusions until the end of the recruitment period, set at six months.

A Scientific Committee validates the scientific writing, a Steering Committee supervises the clinical operations of the project.

Collected data are managed by the DACIMA Clinical Suite®, the electronic data capture platform which complies with the FDA 21 CFR part 11 requirements (Food and Drug Administration 21 Code of Federal Regulations part 11), the HIPAA specifications (Health Insurance Portability and Accountability Act), and the ICH standards (International Conference on Harmonisation). A local authorization by the National Agency of Personal Data Protection will be obtained prior to study kick-off.

Eligibility criteria: Inclusion Criteria:

* Patients with psoriasis
* Informed and written consent

Exclusion Criteria:

* Any dermatology disease other than psoriasis

Primary outcomes:
measure: Psoriasis types
timeFrame: At inclusion
Secondary outcomes:
measure: Demographic
timeFrame: At inclusion
measure: Safety assessment of psoriasis medical treatment
timeFrame: At inclusion
Other outcomes:
Locations:
city: Tunis
country: Tunisia
facility: Société Tunisienne de Dermatologie et de Vénéréologie
Study officials:
affiliation: University Hospital of Habib Thameur, Ben Arous, Tunisia
name: Houda Hammami, MD
role: STUDY_CHAIR
affiliation: University Hospital of Farhat Hached, Sousse, Tunisia
name: Mohamed Denguezli, MD
role: STUDY_CHAIR
affiliation: dr.asmahanesouissi@gmail.com
name: Asmahen Souissi, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05882838: The Level of Knowledge and Awareness of Myofascial Pain Syndrome in the Turkish Population
Official title: The Level of Knowledge and Awareness of Myofascial Pain Syndrome in the Turkish Population
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Myofascial Pain Syndrome
Lead sponsor: Uskudar State Hospital
Sponsor class: OTHER_GOV
Collaborators: name: Başakşehir Çam & Sakura City Hospital
First posted: 2023-05-31
Enrollment: 85
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who applied to the physical medicine and rehabilitation outpatient clinic and gave consent to participate in the study.

Brief summary: This study aimed to assess the level of knowledge and awareness of myofascial pain syndrome (MPS) among the Turkish population.

Detailed description: The study will employ a cross-sectional design to assess the level of knowledge and awareness of myofascial pain syndrome (MPS) in the Turkish population. A representative sample of individuals will be selected for participation in the survey. A structured questionnaire will be developed specifically for this study, consisting of questions related to the understanding, recognition, and management of MPS. The questionnaire will be administered through face-to-face interviews. Data collected from the survey will be analyzed using appropriate statistical methods to determine the overall level of knowledge and awareness of MPS among the Turkish population.

Eligibility criteria: Inclusion Criteria:

* Giving consent.

Exclusion Criteria:

* Not giving consent.
* Any illness or disability that can prevent filling out the form or communicating.

Primary outcomes:
measure: Level of Knowledge and Awareness of Myofascial Pain Syndrome in the Turkish Population
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Uskudar State Hospital
name: Mustafa H Temel, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01410838: Effects of Monosodium Glutamate on Energy Balance and Eating Behavior
Official title: Effects of Ingesting Monosodium Glutamate (MSG) on Energy Balance and Eating Behavior Following Moderate Energy Restriction and Weight Loss in Overweight Women
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Weight Gain
Food Preferences
Keywords: Obesity
Food preferences
Eating Behavior
Lead sponsor: USDA, Western Human Nutrition Research Center
Sponsor class: FED
Collaborators: name: Ajinomoto USA, INC.
First posted: 2011-08-05
Enrollment: 44
Sex: FEMALE
Minimum age (years): 19
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: This study will test whether regular consumption of Monosodium Glutamate (MSG) immediately prior to each of the three major meals (breakfast, lunch, dinner) inhibits body weight and fat regain following a period of moderate, yet clinically significant weight loss.

Detailed description: The proposed study enables us to assess the long term effects of consuming MSG on body weight regain following weight loss.

Eligibility criteria: Inclusion Criteria:

* Women
* Age 19-45
* BMI 27-35
* Blood pressure \<140/90
* Non-smoking

Exclusion Criteria:

* Anemic: hgb \< 11.5 mg/dL
* Sensitivity to MSG (self reported)
* Pregnant or planning to get pregnant
* Taking medication for hypertension, depression, or weight loss
* Diabetic
* Vegetarian
* MRI Contraindications: internal metal, braces on teeth, history of metal in the eye, claustrophobia
* blindness or heavily corrected vision
* not fluent in English

Primary outcomes:
measure: Change in body weight
timeFrame: weeks 11, 12, and 25
Secondary outcomes:
measure: Change in body fat
timeFrame: weeks 11 and 25
measure: Change in eating behavior
timeFrame: weeks 11, 12 and 25
measure: Change in resting energy expenditure
timeFrame: weeks 11, 12, and 25
Other outcomes:
Locations:
city: Davis
country: United States
facility: Western Human Nutrition Center, University of California Davis
state: California
Study officials:
affiliation: WHNRC, ARS, University of California Davis
name: Kevin Laugero, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03163238: Dexmedetomidine and the Inflammatory Response in Pediatric Cardiac Surgery
Official title: The Effect of Dexmedetomidine on the Inflammatory Response in Children Under Congenital Heart Disease Repair With Cardiopulmonary Bypass: A Randomized Controlled Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Cardiac Surgical Procedures
Keywords: Dexmedetomidine
Congenital Heart Disease
Cardiopulmonary Bypass
Interleukin
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2017-05-23
Enrollment: 60
Sex: ALL
Minimum age (years): 1
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Cardiopulmonary bypass-assisted surgery initiates a systemic inflammatory response induced by extrinsic (e.g. anesthesia, contact activation within the extracorporeal circuit, endotoxemia) and intrinsic (e.g. tissue damage, endothelial cell activation, ischemia-reperfusion injury of myocardium) factors. This may either be mild or lead to a more severe clinical condition. Inflammation after pediatric open heart surgery is a parameter affecting also duration of mechanical ventilatory support. Dexmedetomidine use was associated with a reduced increase in plasma IL-1, IL-6, TNF-a, and INF-g levels

Detailed description: Dexmedetomidine will be used during Cardiopulmonary bypass-assisted surgery for pediatric cardiac surgery

Eligibility criteria: Inclusion Elective repair of congenital heart disease with cardiopulmonary bypass Exclusion Reintervention surgery requirement for blood products from the start of CPB, preoperative intake of corticosteroids, deep hypothermia, those with preoperative low cardiac output, those with non-palpable peripheral pulses before surgery (e.g., accompanying coarctation of the aorta) or ischemic time during cardiopulmonary bypass more than 90 minutes

Primary outcomes:
measure: Infilamatory response
timeFrame: Within the first 24 hours
Secondary outcomes:
measure: Sedation score
timeFrame: Within the first 24 hours
measure: Length of mechanical ventilaton
timeFrame: Within 7 days
measure: Length of ICU stay
timeFrame: Within 7 days
measure: Length of hospital stay.
timeFrame: Within 7 days
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Faculty of Medicine
Study officials:
affiliation: Associate profossor of anesthesiology
name: Sayed K Abd-Elshafy, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06080438: Effect of Topical Botulinum Toxin Eyedrop on Palpebral Fissure
Official title: The Effect of Topical Botulinum Toxin Eyedrop on Palpebral Fissure Height, Ocular Surface and Tearing
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Tears; Excess
Eyelid Spasm
Lead sponsor: University of Miami
Sponsor class: OTHER
First posted: 2023-10-12
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this research study is to test if Topical (applied to the surface of the eye) Botulinum Toxin temporarily lowers the upper eyelid and makes the eyelid appear less open and thereby affects the eye surface and decreases reflexive tearing.


Eligibility criteria: Inclusion Criteria:

* Adults aged 18 and above that present to the oculoplastic and reconstructive surgery department that are able to provide informed consent to participate
* Presence of upper eyelid retraction or asymmetry( \>1mm)

Exclusion Criteria:

* Adults unable to consent
* Individuals less than 18 years of age
* Prisoners
* Pregnant women. o Patients will be asked if they are pregnant by research staff before participation in the study.

Women who are breast-feeding

* Known contradictions or sensitivities to study medication
* Grossly abnormal lid margins, anatomical abnormalities
* Variable ptosis or eyelid position (e.g., myasthenia gravis, blepharospasm)
* Any ocular or systemic condition that, in the opinion of the investigator, would confound study data, interfere with the subject's study participation, or affected the subject's safety or trial parameters
* Presence of an active ocular infection
* Inability to sit comfortably for 15 - 30 minutes
* Botulinum toxin injection in the eyelids during the past 3 weeks.
* Neuromuscular disorders (e.g., Parkinson's disease or myasthenia gravis)
* Medication use known to interfere with the effects of botulinum toxin-A within the previous 1 month (e.g., aminoglycoside or benzodiazepines),
* Previous history of hypersensitivity reactions to botulinum toxin-A
* Dysfunction of tear production or secretion (e.g., meibomian gland dysfunction or Sjogren's syndrome),

Primary outcomes:
measure: Change in Palpebral Fissure Height
timeFrame: baseline and Day 3
Secondary outcomes:
measure: Corneal Staining Density
timeFrame: Baseline
measure: Corneal Staining Density
timeFrame: Day 3
measure: Change in Tearing
timeFrame: baseline and Day 3
Other outcomes:
Locations:
city: Miami
country: United States
facility: University of Miami
state: Florida
Study officials:
affiliation: University of Miami
name: Wendy Lee, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02210338: A Comparison of the C-mac and Bonfils Intubation Fibrescope
Official title: A Comparison of the C-mac and Bonfils Intubation Fibrescope for Tracheal Intubation in Patients With a Simulated Difficult Airway
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Intubation
Airway
Lead sponsor: Singapore General Hospital
Sponsor class: OTHER
First posted: 2014-08-06
Enrollment: 64
Sex: ALL
Minimum age (years): 21
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study aims to determine the better device to facilitate intubation in patients with a limited neck movement and small mouth opening. This may help anesthesiology as well as emergency medicine practitioners and departments to decide when choosing between these two conceptually similar device. The hypothesis to be tested is that the C-MAC® is more superior when compared to the Bonfils Intubation Fibrescope in success of intubation, time to intubation and complication rate in patients with a fixed cervical collar.


Eligibility criteria: Inclusion Criteria:

* Patients undergoing elective surgery under general anaesthesia who require endotracheal intubation

Exclusion Criteria:

* Patients with history of previous difficult endotracheal intubation
* Patients with two or more predictors of difficult mask ventilation or difficult intubation or the combination of both
* Patients with ASA (American Society of Anesthesiologists) grading of III and above are excluded from the study, as well as patients with 2 or more predictors for difficult mask ventilation or difficult intubation or the combination of both.
* Patients needing a rapid sequence induction for rapid securement of the airway
* Pregnant women
* Patients below the age of 21 years old
* Patients unfit to give consent

Primary outcomes:
measure: Success of intubation on first attempt
timeFrame: up to 10min - from time of induction to appearance of end tidal carbon dioxide on capnograph after first attempt at intubation
Secondary outcomes:
measure: Time taken to successful intubation
timeFrame: up to 10min - from time of induction to appearance of end tidal carbon dioxide on capnograph after successful intubation
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: Singapore General Hospital
Study officials:
affiliation: Singapore General Hospital
name: Theodore GL Wong
role: PRINCIPAL_INVESTIGATOR
References:
citation: Abdullah HR, Li-Ming T, Marriott A, Wong TG. A comparison between the Bonfils Intubation Fiberscope and McCoy laryngoscope for tracheal intubation in patients with a simulated difficult airway. Anesth Analg. 2013 Nov;117(5):1217-20. doi: 10.1213/ANE.0b013e3182a46fa9.
Clinical trial NCT02067338: Epidural Low Dose Morphine in Postoperative Pain After Posterior Lumbar Spinal Surgery
Official title: The Effect of Epidural Low-dose Morphine-soaked Microfibrillar Collagen Sponge in Postoperative Pain Control After Posterior Lumbar Spinal Surgery: a Randomized, Double-blind, Placebo-controlled
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Morphine
Lead sponsor: Mahidol University
Sponsor class: OTHER
First posted: 2014-02-20
Enrollment: 19
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The effect of epidural low-dose morphine-soaked microfibrillar collagen sponge in postoperative pain control after posterior lumbar spinal surgery: a randomized, double-blind, placebo-controlled study


Eligibility criteria: Inclusion Criteria:

* Age \> 18 Yrs
* Good orientation and communication

Exclusion Criteria:

* opioids or sulfonamides allergy
* Contraindication for use
* Epidural morphine
* Selective COX 2 inhibitor
* Patient-controlled analgesia (PCA)
* ASA class \> 3
* BMI ≥ 35 kg/sq.m.
* Preoperative use of opioids within 6 Wks
* Intraoperative bleeding \> 1000ml

Primary outcomes:
measure: VAS measurement was recorded at twenty-four hour after posterior lumbar spinal surgery then compare VAS between low-dose 1 mg morphine-soaked microfibrillar collagen sponge method with normal saline soked
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Bangkoknoi
country: Thailand
facility: Siriraj hospital
state: Bangkok
Study officials:
References: